newsmetry
rusign inget started
macro

Merck: sac-TMT cut risk of death by 32% in endometrial cancer patients

Merck presented Phase 3 TroFuse-005 data showing sac-TMT lowered the risk of death by 32% versus chemotherapy in advanced or recurrent endometrial cancer.

published on Newsmetry
original source published

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →

Newsmetry newsroom

what happened

Merck has published first results from the Phase 3 TroFuse-005 trial of sacituzumab tirumotecan, an investigational antibody-drug conjugate developed with Kelun-Biotech. The data were presented at the ESMO Congress 2026 and published simultaneously in The Lancet, according to TradingView.

In patients with advanced or recurrent endometrial cancer who had received platinum-based chemotherapy and immunotherapy, the drug reduced the risk of death by 32% and the risk of progression or death by 41%. Median overall survival was 19.0 months versus 12.1 months with chemotherapy. The U.S. FDA accepted a Biologics License Application for priority review, with a target action date of June 15, 2027.

Separately, Merck reported the KEYNOTE-C93 trial of Keytruda monotherapy, which cut the risk of progression or death by 43% versus chemotherapy in dMMR tumors.

why it matters

For Merck shares the news strengthens the company's oncology pipeline, but the effect on the broader market is limited because the drug is not yet approved. The FDA decision is the next key milestone for investors.

tags

StockUnited States

instruments

MRKMerck

sources

  1. Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer — TradingView, 26 October 2026 at 15:30 UTC
  2. KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy — TradingView, 26 October 2026 at 15:35 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.

get stories in real time ↗

related stories